A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Trial Profile

A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Aug 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
    • 15 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014, as per ClinicalTrials.gov record.
    • 25 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top